Mercy Medical Center

Summary

Mercy Medical Center is a medical facility located in Baltimore, Maryland. This center is recognized for care of Breast Cancer, Nonalcoholic Steatohepatitis, Hepatitis C, Breast cancer, Cancer and other specialties. Mercy Medical Center is involved with conducting 219 clinical trials across 294 conditions. There are 5 research doctors associated with this hospital, such as David Riseberg, Paul Thuluvath, MBBS, MD, FRCP, Teresa Diaz-Montes, M.D., M.P.H, and Armando Sardi, M.D..

Top PIs

Clinical Trials running at Mercy Medical Center

Breast Cancer

Colorectal Cancer

Breast cancer

Lung Cancer

Bladder Cancer

Pancreatic Cancer

Prostate Cancer

Ovarian Cancer

Pancreatic Neuroendocrine Tumors

Lymphoma

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

Recruiting

2 awards

Phase 3

3 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.

Recruiting

2 awards

Phase 3

40 criteria